Helen Sanger

552 total citations
12 papers, 315 citations indexed

About

Helen Sanger is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, Helen Sanger has authored 12 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cellular and Molecular Neuroscience, 7 papers in Molecular Biology and 3 papers in Physiology. Recurrent topics in Helen Sanger's work include Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (6 papers) and Nicotinic Acetylcholine Receptors Study (3 papers). Helen Sanger is often cited by papers focused on Neuroscience and Neuropharmacology Research (9 papers), Receptor Mechanisms and Signaling (6 papers) and Nicotinic Acetylcholine Receptors Study (3 papers). Helen Sanger collaborates with scholars based in United States, United Kingdom and Australia. Helen Sanger's co-authors include Lisa M. Broad, Adrian J. Mogg, Christian C. Felder, Francesca Pasqui, Stephen M. Fitzjohn, Jack R. Mellor, John Isaac, Paul Goldsmith, David A. Evans and Kimberley Jackson and has published in prestigious journals such as Pain, Cerebral Cortex and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Helen Sanger

12 papers receiving 307 citations

Peers

Helen Sanger
Helen Sanger
Citations per year, relative to Helen Sanger Helen Sanger (= 1×) peers Holger Lehmann

Countries citing papers authored by Helen Sanger

Since Specialization
Citations

This map shows the geographic impact of Helen Sanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Helen Sanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Helen Sanger more than expected).

Fields of papers citing papers by Helen Sanger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Helen Sanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Helen Sanger. The network helps show where Helen Sanger may publish in the future.

Co-authorship network of co-authors of Helen Sanger

This figure shows the co-authorship network connecting the top 25 collaborators of Helen Sanger. A scholar is included among the top collaborators of Helen Sanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Helen Sanger. Helen Sanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Broad, Lisa M., Jeffrey G. Suico, P. Kellie Turner, et al.. (2025). Preclinical and clinical evaluation of a novel TRPA1 antagonist LY3526318. Pain. 166(8). 1893–1908. 3 indexed citations
2.
Thompson, Karen, Chiara Zanato, Sergio Dall’Angelo, et al.. (2023). The atypical ‘hippocampal’ glutamate receptor coupled to phospholipase D that controls stretch‐sensitivity in primary mechanosensory nerve endings is homomeric purely metabotropic GluK2. Experimental Physiology. 109(1). 81–99. 12 indexed citations
3.
Grubisha, Olivera, Elena Ficulle, Helen Sanger, et al.. (2022). Metabotropic Glutamate Receptors Modulate Exocytotic Tau Release and Propagation. Journal of Pharmacology and Experimental Therapeutics. 383(2). 117–128. 8 indexed citations
4.
Felder, Christian C., Paul Goldsmith, Kimberley Jackson, et al.. (2018). Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases. Neuropharmacology. 136(Pt C). 449–458. 64 indexed citations
5.
Mogg, Adrian J., Thomas E. Eessalu, Megan Johnson, et al.. (2018). In Vitro Pharmacological Characterization and In Vivo Validation of LSN3172176 a Novel M1 Selective Muscarinic Receptor Agonist Tracer Molecule for Positron Emission Tomography. Journal of Pharmacology and Experimental Therapeutics. 365(3). 602–613. 8 indexed citations
6.
Bradley, Sophie J., Colin Molloy, Christoffer Bundgaard, et al.. (2018). Bitopic Binding Mode of an M1 Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes. Molecular Pharmacology. 93(6). 645–656. 21 indexed citations
7.
Broad, Lisa M., Helen Sanger, Adrian J. Mogg, et al.. (2018). Identification and pharmacological profile of SPP1, a potent, functionally selective and brain penetrant agonist at muscarinic M 1 receptors. British Journal of Pharmacology. 176(1). 110–126. 9 indexed citations
8.
Williams, Michael T., Matthew R. Skelton, Olivera Grubisha, et al.. (2017). Phosphodiesterase-1b (Pde1b) knockout mice are resistant to forced swim and tail suspension induced immobility and show upregulation of Pde10a. Psychopharmacology. 234(12). 1803–1813. 20 indexed citations
9.
Pasqui, Francesca, Helen Sanger, Adrian J. Mogg, et al.. (2015). Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus. Cerebral Cortex. 26(1). 414–426. 112 indexed citations
10.
Witkin, Jeffrey M., Paul L. Ornstein, Charles H. Mitch, et al.. (2015). In vitro pharmacological and rat pharmacokinetic characterization of LY3020371, a potent and selective mGlu 2/3 receptor antagonist. Neuropharmacology. 115. 100–114. 18 indexed citations
11.
Grubisha, Olivera, Adrian J. Mogg, Helen Sanger, et al.. (2013). Pharmacological profiling of the TRPV3 channel in recombinant and native assays. British Journal of Pharmacology. 171(10). 2631–2644. 18 indexed citations
12.
Sanger, Helen, Lydia Hanna, Olivera Grubisha, et al.. (2012). Pharmacological profiling of native group II metabotropic glutamate receptors in primary cortical neuronal cultures using a FLIPR. Neuropharmacology. 66. 264–273. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026